AIM: To evaluate application value of recombinant bovine basic fibroblast growth factor on dry eye after cataract phacoemulsification combined with intraocular lens implantation.

METHODS: One hundred and forty patients were selected with one dry eye after the surgery above, and randomly divided into control group and observation group. The two groups were treated with polyethylene glycol eye drops and polyethylene glycol eye drops combined with recombinant bovine basic fibroblast growth factor eye gel respectively. We tested their dry eye symptom score, Schirmer Ⅰ test(SⅠt); tear break-up time(BUT)and corneal fluorescein staining before and 1mo after treatment. Finally, statistical analysis of the two groups of efficacy differences were carried out.

RESULTS: Before treatment, there was no significant difference in dry eye symptom score, SⅠt and BUT between two groups(P>0.05). After treatment, the three measured values above were significantly improved within each group by Paired t-test(P<0.05), while only the dry eye symptom score and BUT in observation group were significantly better than the control group(P<0.05). The decrease rate of corneal fluorescein staining score in the observation group was significantly higher than that in control group(P<0.05).

CONCLUSION: For the treatment of dry eye after cataract phacoemulsification combined with intraocular lens implantation, combined application of the traditional artificial tears polyethylene glycol and recombinant bovine basic fibroblast growth factor is more effective than those only using polyethylene glycol. Combined treatment can improve the eye discomfort, prolong the time of BUT, and reduce the corneal fluorescein staining score more significantly. The medicine has certain application value in clinical.